MeSH tree: C08.381.540.140.500
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone ...
Apr 16, 2023
0
63
Knowing whether a tumor might grow or spread to other parts of a patient's body could be key to survival—and now scientists are one step closer to unlocking the ability to predict just that.
Apr 13, 2023
0
119
Proteomics is the study and analysis of proteins, including their structures, functions, interactions, and modifications within a biological system. Humans have approximately 20,000 genes that produce over a million different ...
Mar 29, 2023
0
56
The traditional treatment for early-stage non-small cell lung cancer is a lobectomy, where a surgeon eradicates cancerous tissue by removing an entire lung lobe.
Mar 24, 2023
0
80
Cancer treatments have long been moving toward personalization—finding the right drugs that work for a patient's unique tumor, based on specific genetic and molecular patterns. Many of these targeted therapies are highly ...
Mar 17, 2023
0
91
In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a ...
Mar 16, 2023
0
74
Scientists have long known that mitochondria play a crucial role in the metabolism and energy production of cancer cells. However, until now, little was known about the relationship between the structural organization of ...
Mar 15, 2023
0
405
Metastasis, the process by which cancer spreads beyond its site of origin, is associated with poor clinical prognosis, cancer mortality, and resistance to therapy. Non-small cell lung cancer (NSCLC) in particular, has a high ...
Feb 17, 2023
0
80
Patients with resectable non–small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes, according to results ...
Feb 15, 2023
0
44
Immune checkpoint inhibitors that activate T cells to target cancer cells have greatly improved patient outcomes across a variety of tumor types. But not all patients respond to the therapies. Moffitt Cancer Center researchers ...
Feb 13, 2023
0
66
